Tracy

Tracy was a transgenic sheep created by scientists at the Roslin Institute in Scotland and born in 1990. She was engineered to carry and express a human gene for alpha-1 antitrypsin, a protein whose deficiency can cause serious lung disorders, including emphysema and conditions associated with cystic fibrosis. Her significance was scientific rather than commercial: she demonstrated that a farm animal could be used as a biological production system for a medically relevant human protein. The protein produced in Tracy's milk represented approximately half of the total protein content of the milk, an unusually high expression level for the period. This concentration remained broadly stable beyond the initial lactation period, and comparable expression was later observed in milk from her granddaughters. These results supported the concept of producing pharmaceuticals through genetically modified livestock, an approach sometimes described as pharming. Tracy became notable as the first transgenic farm mammal. Her work formed part of the research environment at Roslin that helped establish the institute as a leading center for animal genetics and biotechnology. She was also a predecessor in the public and scientific narrative surrounding Dolly, the sheep cloned at Roslin later in the 1990s, although Tracy was created through genetic modification rather than cloning. The therapeutic promise of the protein was not ultimately confirmed in human treatment. Clinical testing of the engineered alpha-1 antitrypsin in 1998 reportedly found that patients developed breathing problems, and development of the milk-derived treatment for the relevant lung diseases did not continue. Tracy died in 1997. Because Tracy was an individual research animal rather than a commercial company or consumer product, conventional brand attributes such as headquarters, ownership, product portfolio, executives, and operating markets do not apply.

Tracy was created at the Roslin Institute in Scotland as part of research into the use of genetically modified farm animals to manufacture medically useful proteins. Rather than being bred solely for agricultural traits, she was engineered to produce a human protein in her milk. The target was alpha-1 antitrypsin, a protein that protects lung tissue and whose deficiency is associated with diseases such as emphysema and certain forms of cystic fibrosis-related lung damage. Born in 1990, Tracy became the first transgenic farm mammal. Her creation marked an important step in the development of so-called pharming: using animals as living production systems for recombinant proteins. The approach was attractive because milk could be collected repeatedly and, in principle, could contain substantial quantities of a therapeutic molecule. In Tracy's case, alpha-1 antitrypsin accounted for about 50 percent of the total protein in her milk, a level described as unusually high. The expression level was maintained after lactation, and similar concentrations were observed in milk from her granddaughters, indicating that the engineered trait could be inherited. Tracy's research significance extended beyond the individual animal. She provided evidence that genetic modification could be used to create stable, heritable production lines in livestock. Her story also belongs to the broader history of Roslin's animal biotechnology program, which later gained worldwide attention through Dolly, the cloned sheep. The two animals represented different technologies: Tracy was transgenic, meaning that her genome was altered to include a human gene, whereas Dolly was produced through somatic-cell nuclear transfer. The medical rationale for Tracy's work was that a manufactured form of alpha-1 antitrypsin might help treat people lacking sufficient levels of the protein. However, the therapeutic program did not achieve that objective. Clinical trials reported in 1998 found breathing problems among patients receiving the engineered protein, and work on the milk-based treatment for the relevant lung diseases subsequently stopped. The result illustrates the distinction between successfully expressing a protein in an animal and proving that the resulting product is safe, effective, scalable, and clinically useful. Tracy died in 1997. Her legacy is therefore tied to a completed research project rather than an ongoing organization or commercial brand. She remains a frequently cited example in discussions of transgenic animals, pharmaceutical production in livestock, genetically modified organisms, and the early history of biotechnology.

• 1998

  Clinical development of the treatment was discontinued

  [1]Tracy (sheep)en.wikipedia.org

  Clinical trials of the engineered protein reportedly produced breathing problems in patients, after which research into the milk-based treatment did not continue.

• 1997

  Tracy died

  [1]Tracy (sheep)en.wikipedia.org

  Tracy died after serving as a research animal in the Roslin Institute's transgenic livestock program.

• 1990

  Tracy was born

  [1]Tracy (sheep)en.wikipedia.org

  Tracy was born as a transgenically modified sheep at the Roslin Institute in Scotland.

• 1990

  Human alpha-1 antitrypsin production was demonstrated

  [1]Tracy (sheep)en.wikipedia.org

  Her milk was found to contain a very high concentration of human alpha-1 antitrypsin, reported at approximately half of the total milk protein.

A landmark research animal associated with transgenic livestock, pharmaceutical protein production, and the early development of animal biotechnology.

• Research output · 1990

  Alpha-1 antitrypsin in milk

  Tracy was engineered to secrete human alpha-1 antitrypsin in her milk. The protein reached approximately 50 percent of the total milk protein and remained at a similarly high level after lactation. Comparable expression in her granddaughters indicated that the genetic trait could be inherited. The material was investigated as a possible treatment for lung diseases associated with alpha-1 antitrypsin deficiency, but the related clinical development was not continued after respiratory problems were reported in trials.

• 1998

  Therapeutic development was haltedStrategy

  Background

  Researchers investigated whether alpha-1 antitrypsin produced in transgenic sheep milk could become a treatment for diseases associated with deficiency of the protein.

  Action taken

  Following clinical-trial reports of breathing problems in patients, research into the milk-derived treatment did not continue.

  Aftermath

  Tracy's principal legacy remained proof of concept for transgenic livestock and pharmaceutical protein production rather than an approved therapy.

  Source

1. 1Tracy (sheep)en.wikipedia.org